The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Biopharma Seeks to Add Idiopathic Hypersomnia to Narcolepsy Drug's Label

Research Report
  ()
Harmony Biosciences Holdings intends to conduct a Phase Three trial next year to evaluate Wakix as a treatment for idiopathic hypersomnia, according to an Oppenheimer report. read more >

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

Research Report
  ()
"Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized," noted an H.C. Wainwright & Co. report. read more >

Phase Two Studies Start For Therapy For Chemo-Treated Breast Cancer Patients

Research Report
  ()
New clinical trials for G1 Therapeutics’ Cosela are “central to our investment thesis,” H.C. Wainright & Co. noted in a new research report. read more >

Biotech Firm’s T-Cell Therapy Gets Positive Results in B-Cell Non-Hodgkin’s Lymphoma Study

  ()
Adicet Bio Inc. shares traded 37% higher after the company reported positive interim data from its Phase 1 GLEAN Study of ADI-001, which the firm noted is the first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy. read more >

Biopharma Launches COVID Vaccine Program in South Africa & Mexico

Research Report
  ()
Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains," noted a Nov. 29, 2021 H.C. Wainwright & Co. report. read more >

Antibody-Drug Conjugate Developer Achieves High Objective Response Rates in Ovarian Cancer Study

  ()
ImmunoGen Inc. shares traded 30% higher after the company announced positive topline data from its pivotal Phase 3 SORAYA Trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer. read more >

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer

Research Report
  ()
Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its "Buy" rating for BioNTech SE. read more >

NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial

  ()
Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant. read more >

Gene Therapy Firm's Shares Rise 120% on Topline Data From Pivotal Dystrophic EB Study

  ()
Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK™ in patients diagnosed with Dystrophic Epidermolysis Bullosa, a rare and severe skin disease. read more >

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

  ()
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. read more >

RNA Silencing Platform Firm Receives US$3.3 Billion Buyout Offer From Novo Nordisk

  ()
Shares of Dicerna Pharmaceuticals Inc. traded 78% higher after the company reported it entered into a definitive agreement to be acquired by Novo Nordisk A/S of Denmark for $38.25 per share in cash. read more >

Novavax Submits Request to EMA for Conditional Marketing Authorization for COVID-19 Vaccine

  ()
Shares of Novavax Inc. traded 10% higher after the firm confirmed that the European Medicines Agency is now reviewing its COVID-19 vaccine filing for conditional marketing authorization. The firm advised that an opinion from the agency is expected within a few weeks. read more >

Biotech Co.'s Shares Gain 32% After Posting Meaningful Renal Response Rates in Ph. 2 Lupus Study

  ()
Shares of Kezar Life Sciences Inc. rose to a new 52-week high after the company reported promising interim results from its Phase 2 trial of KZR-616 in patients with lupus nephritis. read more >

EyePoint Pharma Reduces Wet AMD Treatment Burden by 79% after 6 Mo.'s in Phase 1 Trial

  ()
Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022. read more >

Trial of Psilocybin Therapeutic in Treatment Resistant Depression Yields Positive Topline Results

Research Report
  ()
"We believe this data begins to form the basis of an approvable program for Compass Pathways' COMP360" in this indication, noted a BTIG report. read more >

Advanced Medical Genetics Co. Notches 66% YoY Increase in Q3 Revenue

Research Report
  ()
Invitae Corp. reported Q3/21 financial results that highlighted an 89% YoY increase in billable volume to 296,000 tests. Ladenburg Thalmann & Co. Inc. stated in a research note that it has a "Buy" rating for the company with a $55.00/share price target. read more >

Contakt World Technologies Partnership Will Help Satisfy Demand for Vaccine Passport Technology

  ()
Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology. read more >

Microbiome Therapeutics Co.'s Shares Rise on Q3 Earnings & Partnership With Swiss Manufacturing Firm

  ()
Shares of Seres Therapeutics Inc. traded 20% higher after the company reported Q3/21 financial results and announced it is partnering with Bacthera in Switzerland to manufacture medicine for use in c.Diff treatment. read more >

US DEA OKs Use of Psychedelics by This Mental Health Network

  ()
Clinics that deliver novel psychiatric treatment and host clinical trials of psychedelic medicine have positioned Novamind for breakthroughs in mental health treatment. read more >

Key Data Readouts Expected in 2022 for Developer of Cancer Immunotherapies

Research Report
  ()
Results expected are for trials of Jounce Therapeutics' two lead product candidates, vopratelimab and pimivalimab, both monoclonal antibodies, noted a ROTH Capital Partners report. read more >

Programmed T Cell Therapies Co. Receives $250M Investment From Blackstone to Advance Adult Leukemia Treatment

  ()
Autolus Therapeutics Plc. shares traded 28% higher after the company reported that Blackstone Life Sciences is investing up to $250 million in the firm to develop obe-cel in treatment of adult Acute Lymphoblastic Leukemia and advance its broader targeted T- Cell technology platform. read more >

Specialty Pharma Co. Increases Revenues by 22% in Q3; Raises FY Sales and Earnings Forecast

  ()
Shares of brand, generic and injectable drug maker Endo International traded 25% higher after the company reported Q3/21 financial results and raised its FY/21 revenue and EPS guidance. read more >

Precision Medicine Co.'s ASM Treatment Drug Gaining Rapid Market Adoption

Research Report
  ()
Wedbush Securities Inc. advised that global precision therapy company Blueprint Medicines Corp.'s therapeutic AYVAKIT is gaining traction in patients diagnosed with advanced systemic mastocytosis and gastrointestinal stromal tumors. Wedbush reiterated its Outperform rating for the company and raised its 12-month price target by $4.00 to $136.00 per share. read more >

Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands

Contributed Research
  ()
McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom. read more >

SLT Company's 'Cell Replacement in a Bottle' a Powerful Option in Treating Genetic Diseases

Research Report
  ()
BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable "cell replacement in a bottle" as a potential functional cure for genetic diseases. BTIG advised it is initiating coverage on the company with a "Buy" rating and $14/share price target. read more >
Showing Results: 1 to 25 of 108 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"ETU looks like it is at another great 'buy spot' here." ❭
– Clive Maund, CliveMaund.com
"We initiate coverage on OCG with a Speculative Buy rating." ❭
– Stuart McDougall, Research Capital Corporation
"SM identified two structural mineralized systems at La Tigra." ❭
– Thibaut Lepouttre, Caesars Report
"The next area of exploration for MGR is Chihuahua where Margarita is." ❭
– Rick Mills, Ahead of the Herd
"Buying LIO is like stealing." ❭
– Bob Moriarty, 321 Gold